A
Alexander Gallus
Researcher at Flinders Medical Centre
Publications - 142
Citations - 22477
Alexander Gallus is an academic researcher from Flinders Medical Centre. The author has contributed to research in topics: Warfarin & Venous thrombosis. The author has an hindex of 50, co-authored 142 publications receiving 20707 citations. Previous affiliations of Alexander Gallus include Repatriation General Hospital & South Australia Pathology.
Papers
More filters
Journal ArticleDOI
Oral rivaroxaban for symptomatic venous thromboembolism
Rupert Bauersachs,Scott D. Berkowitz,Benjamin Brenner,Harry R. Buller,Hervé Decousus,Alexander Gallus,Anthonie W. A. Lensing,Frank Misselwitz,Martin H. Prins,Gary E. Raskob,Annelise Segers,Peter Verhamme,Phil Wells,Giancarlo Agnelli,Henri Bounameaux,Alexander T. Cohen,Bruce L. Davidson,Franco Piovella,Sebastian Schellong +18 more
TL;DR: Rivaroxaban offers a simple, single-drug approach to the short-term and continued treatment of venous thrombosis that may improve the benefit-to-risk profile of anticoagulation.
Journal ArticleDOI
Oral Apixaban for the Treatment of Acute Venous Thromboembolism
Giancarlo Agnelli,Harry R. Buller,Alexander T. Cohen,Madelyn Curto,Alexander Gallus,Margot Johnson,Urszula Masiukiewicz,Raphael Pak,John F. Thompson,Gary E. Raskob,Jeffrey I. Weitz +10 more
TL;DR: A fixed-dose regimen of apixaban alone was noninferior to conventional therapy for the treatment of acute venous thromboembolism and was associated with significantly less bleeding.
Journal ArticleDOI
Oral Anticoagulant Therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines
Walter Ageno,Alexander Gallus,Ann K. Wittkowsky,Mark Crowther,Elaine M. Hylek,Gualtiero Palareti +5 more
TL;DR: There is a large amount of evidence on laboratory and clinical characteristics of vitamin K antagonists and a growing body of evidence is becoming available on the first new oral anticoagulant drugs available for clinical use, dabigatran and rivaroxaban.
Journal ArticleDOI
Apixaban for Extended Treatment of Venous Thromboembolism
Giancarlo Agnelli,Harry R. Büller,Alexander T. Cohen,Madelyn Curto,Alexander Gallus,Margot Johnson,Anthony R. Porcari,Gary E. Raskob,Jeffrey I. Weitz +8 more
TL;DR: Extended anticoagulation with apixaban at either a treatment dose (5 mg) or a thromboprophylactic dose (2.5mg) reduced the risk of recurrent venous thromboembolism without increasing the rate of major bleeding.
Journal ArticleDOI
Treatment of Venous Thrombosis with Intravenous Unfractionated Heparin Administered in the Hospital as Compared with Subcutaneous Low-Molecular-Weight Heparin Administered at Home
Mmw Koopman,Paolo Prandoni,Franco Piovella,Paul Ockelford,Dees P. M. Brandjes,J. van der Meer,Alexander Gallus,Gérald Simonneau,C H Chesterman,Maria Prins +9 more
TL;DR: In patients with proximal-vein thrombosis, treatment with low-molecular-weight heparin at home is feasible, effective, and safe.